Twinbeech Capital LP Acquires 171,360 Shares of Natera, Inc. (NASDAQ:NTRA)

Twinbeech Capital LP grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 105.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 333,386 shares of the medical research company's stock after purchasing an additional 171,360 shares during the period. Natera accounts for 0.9% of Twinbeech Capital LP's portfolio, making the stock its 28th biggest position. Twinbeech Capital LP owned approximately 0.25% of Natera worth $52,775,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP grew its position in Natera by 15.7% in the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after buying an additional 439,778 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after buying an additional 142,201 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $1.39 during trading hours on Thursday, hitting $152.48. 1,027,618 shares of the company's stock traded hands, compared to its average volume of 1,388,768. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The company has a market cap of $20.82 billion, a price-to-earnings ratio of -86.64 and a beta of 1.79. The company's fifty day simple moving average is $149.18 and its two-hundred day simple moving average is $157.11.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same period in the prior year, the firm earned ($0.56) earnings per share. The business's quarterly revenue was up 36.5% on a year-over-year basis. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity

In other news, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the sale, the director now directly owns 9,704 shares of the company's stock, valued at $1,471,223.44. This represents a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,160,963.60. The trade was a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,436 shares of company stock worth $22,019,079 over the last quarter. Corporate insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NTRA. Barclays upped their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Piper Sandler upped their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Morgan Stanley boosted their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $182.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.